President Trump announces Medicare will cover GLP-1 weight-loss drugs, sparking debate over economic implications and public ...

By Christy Santhosh and Mrinalika Roy April 30 (Reuters) - Eli Lilly significantly raised its full-year profit and revenue ...

U.S. President Donald Trump announced on Friday that the federal government is taking steps to expand access to GLP-1 ...

Medicare delayed a plan to make insurance companies cover GLP-1 drugs Wegovy and Zepbound. Instead, Medicare will cover the ...

The BALANCE program was intended to cover weight-loss drugs for Medicaid beneficiaries, but is delayed. A new solution with ...

Demand for weight loss drugs is ballooning across the U.S. — and Amazon wants in. The Seattle-based tech giant launched its ...

Americans' voracious appetite for GLP-1 weight loss drugs has the nation on pace to spend more than $1 trillion on ...

CINCINNATI (WKRC) - Weight loss drugs like Ozempic and Wegovy are changing more than waistlines—they're quietly transforming how people spend money, what they prioritize, and who can afford better ...

Foundayo is the first oral GLP-1 weight loss pill that doesn't require fasting.

GLP-1 drugs are reshaping the lives of many, but such treatments can come with a side order of stigma, even shame ...

Stopping popular GLP-1 weight-loss drugs may reverse much of their benefit within a year, according to a large modeling analysis, raising questions about how long patients may need to stay on ...

These medications, when carefully monitored, represent a meaningful new option for families who have struggled for years ...